HB6275: Protecting Consumer Access to Generic Drugs Act of 2023
- 1Introduced (current step)
- 2Passed One Chamber
- 3Passed Both Chambers
- 4Became Law
Here is how to read this bill
Start with the summary
It says what the bill does in plain language. The official text is one tab over.
Check where it is
The status badge says how far it has gotten. The History tab lists every step.
Follow it
We will email you when it moves. You need a free account.
Tell someone who votes on it
Email or call the sponsor, or find your own representatives, from the actions panel.
Bill information
Summary
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
Plain-language summary
This bill would ban brand-name drug makers from paying generic drug makers to stay out of the market. It also blocks biological product manufacturers from paying makers of similar biosimilar drugs to delay their entry. Generic drugs and biosimilars are cheaper alternatives to brand-name drugs. The bill aims to protect consumers by ensuring these cheaper options reach the market without delay. The bill was recently introduced in Congress and is now in the early stage of consideration.
AI-generated summary
What can I do?
It's early in the process — messages to the sponsor and your representatives carry the most weight right now.
Contact Your Representatives
Calling or emailing is the most direct way to weigh in — offices tally constituent contacts.
Find Your RepresentativesShare This Bill
Sharing helps others in your district get informed and involved.
HB6275: Protecting Consumer Access to Generic Drugs Act of 2023
Upcoming hearings & events
Sponsors
Marie Gluesenkamp Perez
Primary SponsorCo-sponsors (3)
Sean Casten
Gerald Connolly
Seth Magaziner